General discussion, page-15944

Mark B is also a very compelling witness to the GAD interim readout and the data set gathered from the participating cohort ...

' confidential interim analysis of the outcome so far and we've been really pleased with what we've seen based on those results thus far - we've been able to model the likelihood of detecting a statistically significant difference between our psilocybin arm & our placebo arm and we found that we have greater than 85% chance of detecting that statistical difference with a confidence level of 95% so at this point its the readout we were looking for so this gives us the confidence to proceed with the next steps in the program looking at developing the drug product and engaging regulators'

this commentary from MB is what pricked my ear - I think if you're potentially looking to invest in the psychedelic therapy treatment sector and you understand that 'the next steps in the program looking at developing the drug product and engaging regulators' is in fact establishing the Clarion Clinics psychedelic business asap in parallel with the progress along the regulatory pathway (Bob Cs' guidance here is indeed a considerable moat) ...well you move from your view on the sideline to take a position in that business opportunity - it is indeed a unique opportunity with a benchmarked strategy headed by a very experienced business operator as evidenced in Peters' 90 second brief.....

a very nice part of the mix within the Incannex tent as 2023 continues to unfold very nicely